Search

Displaying results 6791 - 6800 of 10000 in total
  1. Drug

    Brodimoprim

    go.drugbank.com/drugs/DB13795
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Carumonam

    go.drugbank.com/drugs/DB13553
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Covax-19™

    go.drugbank.com/drugs/DB15846
    Investigational

    Phase 2 and 3 trials are planned for September 2020, and the vaccine is expected to launch early in 2021. … Covax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM.

  4. Drug

    Zalutumumab

    go.drugbank.com/drugs/DB12202
    Investigational

    Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer. … Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR).

  5. Drug

    Deltamethrin

    go.drugbank.com/drugs/DB13600
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Ferulic acid

    go.drugbank.com/drugs/DB07767
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    BG-777

    go.drugbank.com/drugs/DB05839
    Experimental

    BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.

  8. Drug

    Zolimidine

    go.drugbank.com/drugs/DB13593
    Experimental

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  9. Drug

    Moroxydine

    go.drugbank.com/drugs/DB13597
    Experimental

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    Friulimicin B

    go.drugbank.com/drugs/DB06087
    Investigational

    It shows strong cidal activity against a number of Gram-positive pathogens which commonly cause serious infections in hospital patients and which are becoming more routinely acquired in the community. … Friulimicin B is a naturally occurring antibiotic produced by a micro-organism, *Actinoplanes friuliensis*.